{"id":"bevacizumab-and-trastuzumab-maintenance-therapy","safety":{"commonSideEffects":[{"rate":"15%","effect":"Hypertension"},{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Fatigue"},{"rate":"6%","effect":"Headache"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGFA, preventing its interaction with its receptors. Trastuzumab is a recombinant humanized monoclonal antibody that binds to HER2, preventing its interaction with downstream signaling pathways.","oneSentence":"Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:16.790Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06819007","phase":"PHASE3","title":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-03-19","conditions":"Ovarian Cancer","enrollment":582},{"nctId":"NCT00520975","phase":"PHASE3","title":"Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-11","conditions":"Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer","enrollment":96},{"nctId":"NCT05640830","phase":"PHASE1, PHASE2","title":"Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy","status":"RECRUITING","sponsor":"Kangbuk Samsung Hospital","startDate":"2023-01-01","conditions":"HER2-positive Advanced Gastric Cancer","enrollment":47},{"nctId":"NCT02291289","phase":"PHASE2","title":"A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-04-17","conditions":"Colorectal Cancer","enrollment":1044},{"nctId":"NCT00543504","phase":"PHASE1","title":"Bevacizumab in Multiple Phase I Combinations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-10-10","conditions":"Advanced Cancer","enrollment":343},{"nctId":"NCT00428922","phase":"PHASE2","title":"Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients","status":"COMPLETED","sponsor":"Bhuvaneswari Ramaswamy","startDate":"2007-06-14","conditions":"Breast Cancer","enrollment":26},{"nctId":"NCT00811135","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-12","conditions":"Breast Cancer","enrollment":88},{"nctId":"NCT01426880","phase":"PHASE2, PHASE3","title":"Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2011-08","conditions":"Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS","enrollment":595},{"nctId":"NCT01367028","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"2011-06","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT00365365","phase":"PHASE2","title":"Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-08","conditions":"Breast Cancer","enrollment":214},{"nctId":"NCT00446030","phase":"PHASE2","title":"Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-03","conditions":"Breast Neoplasms","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Avastin® (bevacizumab)","Herceptin® (trastuzumab)"],"phase":"phase_2","status":"active","brandName":"Bevacizumab and trastuzumab maintenance therapy","genericName":"Bevacizumab and trastuzumab maintenance therapy","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits vascular endothelial growth factor A (VEGFA) and human epidermal growth factor receptor 2 (HER2) Used for Breast cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}